ADMA Biologics, Inc. (ADMA): EBITDA
$199.54M
Year ended 2025-12-31
$232.17M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $199.54M | +35.7% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $147.03M | +390.7% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $29.96M | n/m | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | -$32.25M | n/m | 2025-03-18, From 2022-01-01 |
| 2021-12-31 | -$52.88M | n/m | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | -$60.97M | n/m | 2022-03-24, From 2020-01-01 |
| 2019-12-31 | -$38.17M | n/m | 2021-03-25, From 2019-01-01 |
| 2018-12-31 | -$56.84M | n/m | 2020-03-13, From 2018-01-01 |
| 2017-12-31 | -$36.62M | n/m | 2019-03-13, From 2017-01-01 |
| 2016-12-31 | -$16.86M | n/m | 2018-03-29, From 2016-01-01 |
| 2015-12-31 | -$15.04M | n/m | 2017-02-24, From 2015-01-01 |
| 2014-12-31 | -$15.77M | n/m | 2016-03-23, From 2014-01-01 |
| 2013-12-31 | -$14.83M | n/m | 2015-03-09, From 2013-01-01 |
| 2012-12-31 | -$7.73M | n/m | 2014-03-28, From 2012-01-01 |
| 2011-12-31 | -$4.40M | n/a | 2013-03-06, From 2011-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $199.54M | +35.7% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | -$42.25M | n/m |
| Twist Bioscience Corp (TWST) | 2025-09-30 | -$111.41M | n/m |
| Repligen Corp (RGEN) | 2025-12-31 | $133.91M | +287.5% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $342.38M | n/m |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | -$41.12M | n/m |
| Vericel Corp (VCEL) | 2025-12-31 | $22.59M | +125.4% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | -$367.42M | n/m |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $26.65M | n/m |
Compare ADMA, IMCR, TWST, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗